A single blood sample for stimulated LH assayed by ICMA is useful for monitoring the treatment efficacy of triptorelin depot in girls

References

• Soriano-Guillén L, Argente J. Central precocious puberty, functional and tumor-related. Best Pract Res Clin Endocrinol Metab. 2019;33(3):101262.
   PubMed Web of Science ®Google Scholar
• Brito VN, Latronico AC, Arnhold IJP, et al. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls. J Clin Endocrinol Metab. 2004;89(9):4338–4342.
   PubMed Web of Science ®Google Scholar
• Bangalore Krishna K, Fuqua JS, Rogol AD, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr. 2019;91(6):357–372.
   PubMed Web of Science ®Google Scholar
• Cheuiche AV, da Silveira LG, de Paula LCP, et al. Diagnosis and management of precocious sexual maturation: an updated review. Eur J Pediatr. 2021;180(10):3073–3087.
   PubMed Web of Science ®Google Scholar
• Carel J-C, Eugster EA, Rogol A, ESPE-LWPES GnRH Analogs Consensus Conference Group, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752–e762.
   PubMed Web of Science ®Google Scholar
• Antoniazzi F, Zamboni G. Central precocious puberty: current treatment options. Paediatr Drugs. 2004;6(4):211–231.
   PubMedGoogle Scholar
• Ma Y, Nie S, Ben Z, et al. The dynamic trends of urinary LH and FSH assayed by ICMA during triptorelin stimulation tests in girls – a pilot study. Clin Lab. 2018;64(10):1701–1708.
   PubMed Web of Science ®Google Scholar
• Haber HP, Wollmann HA, Ranke MB. Pelvic ultrasonography: early differentiation between isolated premature thelarche and Central precocious puberty. Eur J Pediatr. 1995;154(3):182–186.
   PubMed Web of Science ®Google Scholar
• Teilmann G, Boas M, Petersen JH, et al. Early pituitary-gonadal activation before clinical signs of puberty in 5- to 8-year-old adopted girls: a study of 99 foreign adopted girls and 93 controls. J Clin Endocrinol Metab. 2007;92(7):2538–2544.
   PubMed Web of Science ®Google Scholar
• Neely EK, Hintz RL, Wilson DM, et al. Normal ranges for immunochemiluminometric gonadotropin assays. J Pediatr. 1995;127(1):40–46.
   PubMed Web of Science ®Google Scholar
• Sathasivam A, Garibaldi L, Shapiro S, et al. Leuprolide stimulation testing for the evaluation of early female sexual maturation. Clin Endocrinol (Oxf). 2010;73(3):375–381.
   PubMed Web of Science ®Google Scholar
• Brito VN, Spinola-Castro AM, Kochi C, et al. Central precocious puberty: revisiting the diagnosis and therapeutic management. Arch Endocrinol Metab. 2016;60(2):163–172.
   PubMed Web of Science ®Google Scholar
• Brito VN, Latronico AC, Arnhold IJ, et al. Update on the etiology, diagnosis and therapeutic management of sexual precocity. Arq Bras Endocrinol Metabol. 2008;52(1):18–31.
   PubMedGoogle Scholar
• Aguirre RS, Eugster EA. Central precocious puberty: from genetics to treatment. Best Pract Res Clin Endocrinol Metab. 2018;32(4):343–354.
   PubMed Web of Science ®Google Scholar
• Howard SR. Interpretation of reproductive hormones before, during and after the pubertal transition-identifying health and disordered puberty. Clin Endocrinol (Oxf). 2021;95(5):702–715.
   PubMed Web of Science ®Google Scholar
• Schubert S, Hvelplund AH, Handberg A, et al. Elevated pre-injection basal luteinizing hormone concentrations are common in girls treated for Central precocious puberty. J Clin Res Pediatr Endocrinol. 2021;13(2):204–211.
   PubMed Web of Science ®Google Scholar
• Kim MS, Hwang PH, Lee D-Y. A gonadotropin-releasing hormone (GnRH) stimulation test before and after GnRH analogue treatment for Central precocious puberty: has the GnRH test been adequately simplified? Indian J Pediatr. 2015;82(11):996–1000.
   PubMed Web of Science ®Google Scholar
• Lawson ML, Cohen N. A single sample subcutaneous luteinizing hormone (LH)-releasing hormone (LHRH) stimulation test for monitoring LH suppression in children with Central precocious puberty receiving LHRH agonists. J Clin Endocrinol Metab. 1999;84(12):4536–4540.
   PubMed Web of Science ®Google Scholar
• Kandemir N, Demirbilek H, Özön ZA, et al. GnRH stimulation test in precocious puberty: single sample is adequate for diagnosis and dose adjustment. J Clin Res Pediatr Endocrinol. 2011;3(1):12–17.
   PubMed Web of Science ®Google Scholar
• Witchel SF, Baens-Bailon RG, Lee A. Treatment of Central precocious puberty: comparison of urinary gonadotropin excretion and gonadotropin-releasing hormone (GnRH) stimulation tests in monitoring GnRH analog therapy. J Clin Endocrinol Metab. 1996;81(4):1353–1356.
   PubMed Web of Science ®Google Scholar
• Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with Central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007;92(5):1697–1704.
   PubMed Web of Science ®Google Scholar
• Silverman LA, Neely EK, Kletter GB, et al. Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of Central precocious puberty: a final report of a phase 3 multicenter trial. J Clin Endocrinol Metab. 2015;100(6):2354–2363.
   PubMed Web of Science ®Google Scholar
• Klein KO, Freire A, Gryngarten MG, et al. Phase 3 trial of a small-volume subcutaneous 6-month duration leuprolide acetate treatment for Central precocious puberty. J Clin Endocrinol Metab. 2020;105(10):e3660–e3671.
   PubMed Web of Science ®Google Scholar
• Lee PA, Luce M, Bacher P. Monitoring treatment of Central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation. J Pediatr Endocrinol Metab. 2016;29(11):1249–1257.
   PubMed Web of Science ®Google Scholar
• Heinrichs C, Craen M, Vanderschueren-Lodeweyckx M, et al. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for Central precocious puberty. Acta Paediatr. 1994;83(6):627–633.
   PubMed Web of Science ®Google Scholar
• Kunz GJ, Sherman TI, Klein KO. Luteinizing hormone (LH) and estradiol suppression and growth in girls with Central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment? J Pediatr Endocrinol Metab. 2007;20(11):1189–1198.
   PubMed Web of Science ®Google Scholar
• Calcaterra V, De Filippo G, Albertini R, et al. Effectiveness of basal LH in monitoring Central precocious puberty treatment in girls. J Pediatr Endocrinol Metab. 2021;34(1):45–50.
   PubMed Web of Science ®Google Scholar
• Neely EK, Wilson DM, Lee PA, et al. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr. 1995;127(1):47–52.
   PubMed Web of Science ®Google Scholar
• Neely EK, Silverman LA, Geffner ME, et al. Random unstimulated pediatric luteinizing hormone levels are not reliable in the assessment of pubertal suppression during histrelin implant therapy. Int J Pediatr Endocrinol. 2013;2013(1):20.
   PubMedGoogle Scholar
• Wiromrat P, Panamonta O. Elevated random luteinizing hormone is an unreliable indicator for pubertal suppression in girls treated with monthly leuprolide for idiopathic Central precocious puberty. J Clin Res Pediatr Endocrinol. 2019;11(3):227–233.
   PubMed Web of Science ®Google Scholar